The Conversation (0)
Advanced Proteome Therapeutics (TSXV:APC) announces that during the 2017 calendar year, it has witnessed very significant progress in APC’s scientific program that has bolstered opportunities for achieving commercial success. As quoted in the press release: As we gather momentum and follow through with next steps in 2018, the Company is poised to obtain several key results …
Advanced Proteome Therapeutics (TSXV:APC) announces that during the 2017 calendar year, it has witnessed very significant progress in APC’s scientific program that has bolstered opportunities for achieving commercial success.
As quoted in the press release:
As we gather momentum and follow through with next steps in 2018, the Company is poised to obtain several key results from the testing of novel ADCs in animal studies. Technology transfer and scale-up of the conjugation technology by our contractual partners for animal testing of several therapeutically validated antibodies and their evaluation as potential ADC products have begun at the National Research Council of Canada (News releases-July18, 2017; November 20, 2017.
Latest News
Outlook Reports world
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES